TB-500 Half-Life

What is the half-life of TB-500?

There is no reliably published human half-life for TB-500, so an honest answer is that the number is not established. Half-life is the time it takes for the amount of a compound in the bloodstream to drop by 50 percent. To report it with confidence, you need a controlled study that measures plasma concentration over time in a defined species, by a defined route, using a validated assay. For TB-500 specifically, that human dataset is not present in the verifiable published literature at the time of writing. Figures circulating on forums and product pages are not traceable to a peer-reviewed human pharmacokinetic trial, so we do not repeat them as fact.

What is TB-500 versus thymosin beta-4?

TB-500 is a lab-synthesized peptide that vendors describe as a fragment related to thymosin beta-4, an endogenous peptide, but the two are not automatically interchangeable in pharmacokinetic terms. Thymosin beta-4 is a small peptide found naturally in many tissues and is studied for its role in cell migration and repair processes. "TB-500" is a commercial name, and different products sold under it may differ in exact sequence, purity, and formulation. Because pharmacokinetics depend on the precise molecule and how it is prepared, half-life data for one preparation does not transfer cleanly to another. Treat "TB-500" and "thymosin beta-4" as related but distinct labels until a specific product's identity is confirmed by analysis.

Why is human half-life data for TB-500 so scarce?

Because most TB-500 and thymosin beta-4 work sits in preclinical models, not completed human pharmacokinetic trials. Small peptides are often expensive to study in people, and research-use compounds rarely progress through the phased human trials that generate clean half-life numbers. This mirrors a broader pattern across the research-peptide space: for BPC-157, another widely discussed repair peptide, human data is very limited and animal data dominates the record (PMC7096228). When the human dataset is thin, the responsible move is to say so rather than present an animal-derived or estimated figure as if it applied to people.

How would you even measure a peptide half-life?

You measure it by dosing a defined amount, then sampling blood at set intervals and plotting how concentration falls over time. Several factors shape the result:

Because none of these columns is filled by a strong human dataset for TB-500, any confident "the half-life is X hours" claim is running ahead of the evidence.

Do published peptide studies give a useful comparison point?

Yes, in the sense that other secretagogues and peptides show how much duration depends on the exact molecule, not the class. For example, CJC-1295 was engineered to sustain growth hormone and IGF-1 levels over an extended window (Teichman et al., 2006), while ipamorelin acts as a more selective, shorter-acting growth hormone secretagogue (Raun et al., 1998). Tesamorelin, a peptide with completed human trials, reduced visceral adipose tissue by about 15 percent (Falutz et al., 2007), which shows what a well-studied peptide record looks like. The contrast is the point: peptides with real human trials have measurable, reportable pharmacology, and TB-500 does not yet sit in that category.

What should a buyer take away about TB-500 half-life claims?

Treat every published "half-life in hours" figure for TB-500 as unverified until you can trace it to a real human study. A trustworthy pharmacokinetic claim names the species, route, sample size, timepoints, and assay. If a product page gives a clean number with no citation, that number is marketing, not data. The candid summary is that the science needed to state a human half-life for TB-500 has not been published in a form we can verify, so we decline to invent one.